HOME >> MEDICINE >> NEWS
US FDA grants full approval to DOXIL(R) following submission of phase III data

Bridgewater, N.J. February 7, 2005 -- The U.S. Food and Drug Administration (FDA) has granted full approval to DOXIL (doxorubicin HCl liposome injection) for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. DOXIL, marketed in the United States by Tibotec Therapeutics, Division of Ortho Biotech Products, L.P., originally received accelerated approval for refractory ovarian cancer in June 1999. As a result of the full approval, the product label for DOXIL has been updated to include survival, time to disease progression and tumor response rate data from a randomized Phase III clinical study.

Under accelerated approval, DOXIL was indicated for the treatment of metastatic ovarian cancer in patients with disease that was refractory to both paclitaxel- and platinum-based chemotherapy regimens. This approval was based on tumor response rates from three Phase II studies. According to the terms of the accelerated approval, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) completed a randomized Phase III clinical study to formally demonstrate the drug's clinical benefit in patients with relapsed ovarian cancer. In March 2004, J&JPRD submitted a supplemental new drug application (sNDA) based on data from the Phase III study.

"The Phase III data provide evidence of the product's clinical benefit for patients with relapsed ovarian cancer," commented Alan N. Gordon, M.D., of the University of Arizona School of Medicine and Arizona Gynecologic Oncology, in Phoenix, Ariz., and lead author of the Phase III study, known as DOXIL Study 30-49.

In the randomized, multi-center, open-label, Phase III study, 474 patients with recurrent epithelial ovarian cancer were randomly assigned to receive either DOXIL 50 mg/m2 every 28 days or topotecan HCl 1.5 mg/m2/day for five consecutive days every 21 days. A total of 239 patients received DOXIL; 235 patients received
'"/>


7-Feb-2005


Page: 1 2 3

Related medicine news :

1. UNH launches 2nd spinout company with NIH grants
2. Disease testing for immigrants: Discrimination disguised as public health policy
3. Four teams awarded inaugural translational cancer research grants
4. Immigrants, beware: Living in the United States is fattening
5. Prevalence of obesity among immigrants increases with longer residency in US
6. FDA grants accelerated approval of TYSABRI, formerly antegren, for the treatment of MS
7. Dana-Farber receives CDC grants to develop health promotion/prevention programs in the work place
8. Speech recognition experts at OGI School of Science & Engineering receive nearly $700,000 in grants
9. Should compulsory screening of immigrants be part of UK public health policy?
10. NIH grants support health disparities biomedical research
11. NCCAM awards planning grants for International Centers for Research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)... ... March 22, 2017 , ... Influence ... its digital marketing solutions have enabled Children’s Hospital of The King’s Daughters (CHKD) ... , Recognizing the value of a digital marketing approach, the 206-bed pediatric teaching ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Burke Medical Research ... translate advances in basic neuroscience at the BMRI labs into new and improved ... improve movement, vision, and cognition impaired by stroke, traumatic brain injury, cerebral palsy, ...
(Date:3/22/2017)... , ... March 22, 2017 , ... The Vanderbeck Agency, ... the greater Nassau County region, is embarking on a combined charity effort with the ... , For the last 25 years, the Great Neck Breast Cancer Coalition has worked ...
(Date:3/22/2017)... ... , ... Chris Humphrey Insurance Agency, a North Carolina firm offering asset protection ... region, is initiating a charity event to raise support for five year old Dillyn, ... on a Friday evening in September 2014. At the time, Dillyn was only four ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... for providers while creating a positive patient experience. , HealthiPASS has further ... and empowers patients by helping them understand their financial responsibility. “Our latest ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... RADNOR, Pennsylvania , 22. März 2017 ... führende unabhängige und weltweit tätige Anbieter von ... gibt heute den Erwerb von EPL Archives ... biologischer Stoffe, der Kunden im kompletten Zyklus ... bei Verwahrung von Proben, Speicherung von Dokumenten ...
(Date:3/22/2017)... DUBLIN , Mar 22, 2017 Research ... Packaging Market Analysis & Trends - Industry Forecast to 2025" ... ... at a CAGR of around 7.1% over the next decade to ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... March 22, 2017 Piramal Pharma ... (CDMO), held a special event to introduce the new ... Lexington, Kentucky . The inaugural event was ... Chairman Ajay Piramal, and Piramal Pharma Solutions CEO, ... ...
Breaking Medicine Technology:
Cached News: